Important: New Login Process

We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.

  • If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
  • If you log in with a username and password, you will be prompted to set a new password before accessing your account.

Go to the Login Page to get started.

We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.

BioCentury
PODCAST | Product Development

Radiopharma ɑ-emitters, AZ’s Galbraith and LNPs — a BioCentury podcast

Plus the latest data from Roche in the oral obesity race

By Stephen Hansen, Director of Biopharma Intelligence
July 22, 2024 11:21 PM UTC

Alpha-emitting isotopes are the latest trend in the hot radioligand space, but there’s debate about which isotope offers the best attributes for optimizing safety and efficacy, as well as manufacturing and distribution. On the latest BioCentury This Week podcast, BioCentury’s editors discuss the benefits and challenges that come with developing radiopharmaceuticals using lead-212 versus its more well-known counterpart actinium-225.

They also discuss Editor-in-Chief Simone Fishburn’s conversation with Susan Galbraith, EVP of Oncology R&D at AstraZeneca plc (LSE:AZN; NASDAQ:AZN), about the future of cancer research and the pharma’s comeback in the space.

The conversation also dives into the state of innovation in targeting lipid nanoparticles to specific tissues beyond the liver, and the most recent oral GLP-1 obesity data from Roche (SIX:ROG; OTCQX:RHHBY). 

For information on opportunities to sponsor The BioCentury Show and the BioCentury This Week podcast, please email conferences@biocentury.com.

Purchase Reprint/Distribution Rights
Continue reading with a free trial.
Start a Free TrialLog In
Or Purchase This Article